Takeda Pharmaceutical will divest Takeda Consumer Healthcare Company Limited (TCHC) to The Blackstone Group for $2.3 billion as the company continues to divest non-core business units in order to pare down debt accumulated from its $62 billion acquisition of Shire Plc.
Takeda continues to divest the company’s over-the-counter business operations and struck a deal for its U.S. offerings with The Blackstone Group, a U.S.-based investment fund valued at $2.37 billion.
More drugs are being assessed as potential treatments against the pandemic as the battle against COVID-19 continues. Researchers in New York are seeking to determine if the active ingredient in an over-the-counter heartburn medication will have any impact on the disease.
The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.
Arcadia Consumer Healthcare Inc., (formerly Kramer Laboratories Inc.) a recognized leader in the consumer healthcare industry, announced that the company completed the acquisition of the U.S. rights to the Kaopectate brand from Sanofi.
Takeda Pharmaceutical Co. Ltd. will sell some over-the-counter and prescription drugs to Germany’s Stada Arzneimittel AG for a total value of $660 million.
An independent expert panel to the U.S. FDA recommended approval of GlaxoSmithKline Plc’s over-the-counter nicotine oral spray that aims to help smokers quit their addiction.
The new global pharmaceutical company combines Mylan N.V. with Upjohn, Pfizer Inc.’s off-patent branded and generic established medicines business.
French drugs and healthcare group Sanofi signed a rights deal with Roche for Tamiflu in the United States.
Aspen Pharmacare said Mylan NV exercised an option to buy the South African drugmaker’s portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).